Skip To Main Content
Eduardo Barbieri on Muck Rack

Eduardo Barbieri

As seen in: AIChE Journal, Wiley Online Library, ACS Publications, Royal Society of Chemistry, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eduardo

Contact Eduardo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

DendriPep Nanocoats: Substrate-Agnostic, Self-Assembling Constructs with Shear-Controlled Thickness and Permeability

|
By Ryan Smith, Srivatsan Ramesh, Eduardo Barbieri, Juliana N. O’Brien
| ACS Publications
Open in Who Shared Issue with article?

Integrating Affinity Chromatography in the Platform Process for Adenovirus Purification

|
By Yuxuan Wu, Eduardo Barbieri, WILLIAM SMITH, Biomanufacturing Training
| Wiley Online Library Verified
1 Introduction The adoption of Adenoviral vectors (AdVs) for delivering mRNA vaccines during the COVID-19 pandemic has brought AdV back into the spotlight of the biomanufacturing community. Since 2020, the clinical trials employing AdVs for cancer therapy (tumor suppressor and suicide genes, and immunostimulatory genes) (Barton et al. 2006; Gao et al. 2020; Sorensen et al. 2009; Wang et al. 2009), vaccine development (Afkhami et al. 2016; Sakurai et al. 2022; Thacker et al.
Open in Who Shared Issue with article?

Developing a process of lentivirus purification from recombinant fluids using peptide affinity ligands

|
By Eduardo Barbieri, Gina N. Mollica, Sobhana A. Sripada, Shrirarjun Shastry
| AIChE Journal Verified
1 INTRODUCTION Modern gene and cell-based therapies offer hope to patients with debilitating or life-threatening diseases and aggressive forms of cancer.1 A milestone in cell therapy was reached in 2022, with the 10th anniversary of the first pediatric patient of acute lymphoblastic leukemia, Emily Whitehead, cured with Chimeric antigen receptor T (CarT) cell therapy.2 To date, the United States Food and Drug Administration (FDA) has approved more than 30 cell and gene therapies to fight a...
Open in Who Shared Issue with article?
See all 13 articles